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Introduction
Infections account for 26-36% of all neonatal deaths
worldwide.1,2 Current World Health Oragnisation (WHO)
recommendation for the treatment for sepsis in infants
younger than two months include hospitalisation and
parenteral therapy with antibiotic regimens containing
penicillin or ampicillin combined with an aminoglycoside.3
These recommendations are inadequately followed in
developing countries as most births take place at home,
and families of sick newborns are unable to access hospital
care because of inefficient health systems, socioeconomic,
logistic and cultural constraints.4-7Many of these infants die
at home without receiving any therapy. The Millennium
Development Goal (MGD) for child survival cannot be
attained without substantial decrease in infection-specific
neonatal mortality.8 Thus approaches for detecting and
managing serious infections within the community, at
home or first-level health facilities are increasingly being
explored in settings where there are delays, reluctance and
constraints in seeking secondary or tertiary level care.9
The evidence for effectiveness of community-based
treatment of neonatal sepsis is accumulating.10 Bang et al
showed a 29% decline in the neonatal mortality in rural
India by administering home-based oral cotrimoxazole,
and intramuscular gentamicin to newborns with sepsis by
village health workers.11 A 34% reduction in neonatal
mortality was observed in Bangladesh by treatment of
neonatal sepsis with procaine penicillin and injection
gentamicin at home by community health workers.12 A
study of community management of suspected neonatal
sepsis in Pakistan showed almost 86% success rate using
3 different antibiotic regimens, two of which included
injection gentamicin.9
Although community use of injection gentamicin is
effective for neonatal sepsis, its safety in these settings
has not been clearly established. Moreover, there are
concerns that indiscriminate use could lead to serious
ototoxicity in such environments, especially if minimally-
trained health workers are responsible for treatment
decisions and drug administration. A Cochrane review
compared the results of four studies which assessed
hearing impairment caused by gentamicin use in
neonates in hospital settings. Three of these studies
showed no hearing impairment, but in one study, two out
of 13 neonates developed hearing impairment.13
However, all the studies regarding safety of gentamicin in
neonates were conducted in hospitalised children and the
question of its safety when used at large scale in
community settings remains unanswered. The current
study sought to determine the risk of hearing loss
associated with gentamicin exposure in the first 60 days
of life when gentamicin was used for community-based
management of sepsis where referral had failed.
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Abstract
Objective: To determine the safety of gentamicin when used in a community setting to treat neonatal sepsis. 
Methods: The study was conducted in peri-urban areas of Karachi from September 2009 to April 2010. The exposed
group consisted of children 6 months to 3 years of age who were treated for sepsis during 0-2 months of age in the
community, with a regimen that included gentamicin for at least five days. The control group included children from
the same area who never received gentamicin. The outcome measure was hearing loss, which was assessed by
Brainstem Evoked Response Audiometry. 
Results: Of the 255 children enrolled, 125 (49%) received gentamicin, while 130 (51%) were not exposed to
gentamicin. Children in the gentamicin exposed group were not at increased risk for hearing loss compared to
controls (n=30; 30.9% vs. n=33; 31.4%, RR 0.98; 95% CI: 0.60-1.61). Children with history of ear discharge (RR 1.7) and
children with family history of deafness (RR 2.0) were more at risk for having hearing loss. 
Conclusion: No association was found between hearing loss and gentamicin exposure in a community setting for
the management of sepsis in the first two months of life. 
Keywords: Aminoglycoside, Gentamicin, Ototoxicity, Community management, Sepsis, Neonate. (JPMA 63: 1226; 2013)
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Patients and Methods
The retrospective cohort study was conducted from
September 2009 to April 2010 in peri-urban coastal areas
of Karachi. These are socio-economically depressed areas
with fishing and livestock rearing as the major income-
generating activities. The Aga Khan University's (AKU)
primary healthcare centre is the major healthcare
provider for children.
The primary objective was to determine the risk of
hearing loss associated with gentamicin exposure in the
first 60 days of life in children compared to those who had
never received gentamicin. The exposed study population
consisted of children who had previously been treated for
sepsis at the area primary care clinics run by the AKU's
Department of Paediatrics and Child Health with a
regimen that included gentamicin. Sepsis had been
diagnosed by study physicians using pre-defined clinical
criteria14 and the infants received injectable procaine
penicillin and gentamicin (dose 5 mg/kg once daily) for 7
days if the family refused facilitated referral. Antibiotics
were administered by study physicians. Young infants
with meningitis had been treated with ceftriaxone, and
these children were excluded from the exposed
population as they had not received gentamicin.
Data for gentamicin exposed and non-exposed groups of
infants were taken from the records of these clinics. Inclusion
criteria in the gentamicin exposed group comprised infants
who were given injection gentamicin in the dose of 5mg/kg
in the first 60 days of life for at least 5 days, at least 6 months
prior to enrollment in the study. Inclusion criteria in the
gentamicin non-exposed group comprised infants who had
never received gentamicin, and in whom complete records
of treatment received at the relevant health centres were
available. Children were excluded if they had any congenital
anomaly, were having ear discharge at the time of study, or if
they had received injection gentamicin outside the neonatal
sepsis management programme. Crude relative risks (RR)
with 95% confidence intervals (CI) were calculated using Cox
proportional hazard regression algorithm in order to observe
associations between outcome and other independent
variables at univariate level. Multivariable analysis was done
using the same algorithms by calculating adjusted relative
risks (ARR) with 95% CI.
After informed consent, baseline characteristics of the
participants were recorded using standard
questionnaires, and hearing was assessed using
Brainstem Evoked Response Audiometry (BERA) test.
BERA was conducted at the neurophysiology laboratory
at the Aga Khan University Hospital (AKUH), where it was
interpreted by trained neurophysiologists. The hearing
loss, if present, was classified as mild (15-30 db), moderate
(31-60 db) or severe (>61 db).The study was approved by
the institutional ethics review committee.
The risk of hearing loss in children in Asia is reported as
4.64/1000.15 It was hypothesised that gentamicin
exposure in the first 60 days of life causes hearing loss in
10% of exposed Pakistani children. Assuming the risk of
hearing loss in gentamicin exposed and non-exposed
children as 10% and 0.46% respectively, with level of
significance of 0.05 achieved a power of 80 per cent for a
minimum of 104 children in each of the exposed and non-
exposed group. An anticipated non-response rate in each
group was assumed as 10%, so we planned to enroll 115
children in each group. 
Results
A total of 255 children were enrolled; 125 (49%) in the
gentamicin exposed group, and 130 (51%) in the non-
exposed group to account for the higher than expected
refusal rate for BERA. BERA was done in 97 (77.6%) gentamicin
exposed children, and in 105 (80.7%) non-exposed children.
The baseline socio-demographic and clinical characteristics in
the two groups were noted (Table-1). 
Some degree of hearing loss was detected in 30 (30.9%)
children in gentamicin exposed group and in 33 (31.4%)
children in the non-exposed group. In the former group,
15 (15.4%) of the 97 children had mild hearing loss,
14(14.4%) had moderate, and 1(1.0%) child had severe
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Table-1: Baseline socio-demographic and clinical factors in children of gentamicin
exposed and non-exposed group.
Gentamicin Gentamicin non- 
exposed (n=97) exposed (n=105)
Age in months (mean±SD) 14.0 ± 7.0 18.0 ± 7.0
Male (n, %) 56 (57.7) 55(52.4)
Consanguinity (n,%) 47(48.5) 47(44.8)
Family history of hearing loss (n, %) 28(28.9) 24(22.9)
Relative with history of hearing loss 
- Immediate relative (n, %) 8(28.6) 13(54.2)
- Maternal relative (n, %) 7(25.0) 4(16.6)
- Paternal relative (n, %) 13(46.4) 7(29.2)
Preterm Birth (n,%) 3(3.1) 1(1.0)
History of delayed cry after birth (n, %) 10(10.3) 10(9.5)
History of neonatal jaundice (n, %) 35(36.1) 33(31.4)
History of ear discharge (n, %) 22(22.7) 31 (29.5)
Care taker's perception of hearing loss (n, %) 5(5.2) 4(3.8)
Age (in months) at which child started
startling (median(IQR)) 6(5,6) 6(5,6)
Age (in months) at which child started
recognizing voice (median (IQR) 6(5,6) 6(6,6)
IQR: Interquartile range.
hearing loss. In the non-exposed group, 17(16.1%) of the
105 children had mild, 13(12.3%) had moderate, and
3(2.8%) had severe hearing loss.
At the univariate level of analysis, children with exposure to
gentamicin during early infancy were not at increased risk
for hearing loss (RR 0.98; 95% CI: 0.60-1.61). Children with a
family history of hearing loss (p<0.008; RR: 1.78; 95% CI:
1.07- 2.95), history of previous ear discharge (p<0.004; RR:
1.85; 95% CI: 1.12=3.06), and whose caretakers perceived
that their child had difficulty in hearing (p<0.03; RR: 2.26;
95% CI: 0.97=5.24) were more likely to have hearing loss
compared to the comparison group. Risk of hearing loss was
also higher in children who had history of neonatal jaundice
(p<0.06; RR: 1.48; 95% CI: 0.89=2.43), but was not statistically
significant. None of the other variables such as age, gender,
mothers' education, consanguinity etc. showed significant
association with hearing loss at univariate level. Therefore,
the final model describing the risk of hearing loss in children
comprised gentamicin exposure, history of ear discharge
and relative with hearing loss (Table-2). Using a multiple
logistic regression model controlling for confounders,
history of ear discharge (RR 1.79; 95% CI: 1.06=2.98), history
of hearing loss in immediate relatives (RR 2.0; 95% CI:
1.09=4.16) and children having history of hearing loss in
maternal relatives (RR 2.7; 95% CI: 1.23=5.87) retained their
significance as independent risk factors for hearing loss,
while exposure to gentamicin (RR 1.05; 95% CI: 0.63=1.75)
continued to be non-significant risk factor for hearing loss. 
Discussion
The study did not find an association between hearing
loss and gentamicin exposure for the management of
sepsis in the first two months of life. This finding was
consistent with results of other studies conducted in
hospitalised children.16 In a four-year randomised
controlled trial comparing the hearing ability in neonates
treated with gentamicin or kanamycin, no difference was
found in auditory function between gentamicin or
kanamycin treatment and control group.17 However,
these prior studies were hospital-based, and their results
may not be applicable for community level use of
gentamicin. Our study is the first to show safety of
gentamicin with regards to ototoxicity when gentamicin
is used in community settings to treat neonatal sepsis. 
A striking 31% of study participants were found to have
hearing loss. While there are no national estimates from
Pakistan, investigators in the UK have reported a 3.5 times
higher prevalence of hearing loss in Asian children
(Pakistani, Indian and Bangladeshi) compared to non-
Asian children (4.64/1000 vs. 1.33/1000 live births).15 Elahi
et al showed 7.9% prevalence of hearing loss in children of
rural Pakistan, but hearing loss was determined by
audiometry, not BERA which is a more sensitive tool to
detect sensorineural hearing loss.18.19 To the best of our
knowledge, this is the first community-based study in
Pakistan to measure hearing loss with the help of BERA.
The etiology of hearing loss in children could be genetic,
acquired or a combination of the two. Untreated middle
ear infections are an important cause of acquired hearing
loss, and the study found that children with history of ear
discharge, presumed to be most likely due to middle ear
infections, were 1.85 times more likely to have hearing
loss compared to other children. Genetics is also likely to
be playing a major role in the high prevalence of hearing
loss seen in the study. Children whose parents or sibling
had hearing loss were at 1.78 fold increased risk (95% CI:
1.07, 2.95) of having hearing loss. A study in UK also found
that positive family history of deafness was more
common in Pakistani children with deafness compared to
white children (66.4% vs. 38.8%).20 Genetically
transmitted hearing loss can be syndromic, i.e., combined
with other conditions, or non-syndromic. In non-
syndromic forms, which occur in about 70% of cases of
hereditary hearing loss, deafness can be inherited by
mitochondrial transmission, i.e.,via the mother lineage.21
We observed that children whose maternal relative had
hearing loss were at highest risk (2.82 fold) for having
hearing loss. This might be due to the fact that the
majority of the respondents in our study were children's
mothers who may have had better recall for their relatives
with hearing loss compared to paternal relatives, and so
hearing loss in paternal relatives did not come out as a risk
factor. Alternatively, this could be due to mutations in
mitochondrial genome, which is maternally inherited.
There is a need for better understanding of the genetic
causes of hearing loss in children in Pakistan so that
appropriate genetic counselling could be done, especially
given the high rate of consanguinity.22
The study assessed hearing impairment in children by
BERA, which has 100% sensitivity and 88% specificity.19
Results of BERA were interpreted by neurophysiologists
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Table-2: Multivariable analysis showing association of variables with hearing loss in
gentamicin exposed and non-exposed children.
Model variable Adjusted Relative 95% confidence
Risk (ARR) interval
Gentamicin exposure 1.05 0.63 - 1.75
Previous history of ear discharge 1.79 1.08- 2.98
Hearing loss in immediate relatives 2 1.02- 3.95
Hearing loss in maternal relatives 2.73 1.27 - 5.87
Hearing loss in paternal relatives 0.89 0.35 -2.28
who were not aware of gentamicin exposure status of the
children. We used the data of neonatal sepsis
management programme for the identification of
gentamicin exposed and non-exposed groups. Thus, the
ascertainment of exposure was reliable as it was not self-
reported. Gentamicin dosage given to study participants
was the WHO recommended dose. 
Although gentamicin use was not associated with hearing
loss in our study, but we would be cautious in assuming
generalisability of these findings. Our study was conducted
in a research setting, where accurate dosing of gentamicin
was ensured by physicians. In programmatic settings, if
workers are not trained and monitored, newborns may be
exposed to inadvertent high doses which may result in
ototoxicity. High prevalence of hearing loss in South Asian
population makes it advisable to develop sensitive and
specific diagnostic tools for the diagnosis of sepsis by
minimally trained health workers so that unnecessary
gentamicin use can be avoided. The other important finding
is the presence of hearing loss in 31% of the children
studied. Further research is recommended to find and
address the causes behind this high prevalence, as hearing
loss in early childhood often remains undiagnosed and
affects children's milestones and cognitive development.
Conclusion
No association was found between gentamicin exposure
and hearing loss in a community setting for the
management of sepsis in the first two months of life.
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